Tag: insights

Florida, July 08, 2025 (GLOBE NEWSWIRE) -- Slate, a leading innovation discovery platform developed by GreyB, has announced the launch of “Prism", a new structured research module to solve complex, constraint-based R&D challenges. Slate Prism breaks down your query, scans thousands of patents and papers, and delivers evidence-backed insights on what works, what doesn’t, and why. It goes beyond simple search results to deliver in-depth analysis of solutions.

According to Precedence Research, the global web3 gaming market size is calculated at USD 37.55 billion in 2025 and is expected to be worth around USD 182.98 billion by 2034, registering a robust CAGR of 19.24% from 2025 to 2034. North America accounted for USD 11.34 billion in 2024 and is poised to maintain its dominance with a double-digit CAGR of 19.40%.

OSLO, Norway (8 July 2025) – TGS ASA (“TGS”), a leading global provider of energy data and intelligence, routinely publishes a quarterly operational update six working days after quarter-end. For Q2 2025, it also includes a financial update.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Hydrogen Technology TIC Market size & share revenue was valued at approximately USD 4.3 Billion in 2024 and is expected to reach USD 5 Billion in 2025 and is expected to reach around USD 18.4 Billion by 2034, at a CAGR of 17.5% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are SGS SA, Bureau Veritas SA, Intertek Group plc, DEKRA SE, TÜV SÜD, DNV GL, TÜV Rhineland, Applus+, TÜV NORD GROUP, UL LLC and others.

The project will include the full suite of Fluence’s innovative storage products, including Gridstack™, a 20-year service contract, Mosaic bidding software, and Nispera asset performance management software

Senior Living Leader Brings Full-Spectrum Industry Experience to Guide AI Transformation Across the Sector

PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’),  a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company.